Sulfasalazine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
以下是根據 Evidence Pack 產生的完整評估報告：
Sulfasalazine: From Inflammatory Arthritis / IBD to Brachydactyly-Syndactyly Syndrome
One-Sentence Summary
Sulfasalazine is a well-established anti-inflammatory agent and disease-modifying antirheumatic drug (DMARD), globally used for inflammatory bowel disease, rheumatoid arthritis, and ankylosing spondylitis; it is not currently registered in the Netherlands market. The TxGNN model assigns it a 99.94% prediction score for Brachydactyly-Syndactyly Syndrome as a potential new indication. However, no clinical trials and no published literature support this direction, and the mechanistic rationale is considered implausible — this prediction is likely a knowledge-graph artefact.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in the Netherlands; globally used for inflammatory bowel disease, rheumatoid arthritis, and ankylosing spondylitis |
| Predicted New Indication | Brachydactyly-Syndactyly Syndrome |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| NL Market Status | Not registered |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Sulfasalazine is a combined anti-inflammatory and DMARD whose therapeutic effects involve NF-κB inhibition, blockade of prostaglandin and leukotriene synthesis, and suppression of pro-inflammatory cytokine production. Its clinical efficacy in inflammatory bowel disease, rheumatoid arthritis, and spondyloarthritis is well established globally.
Brachydactyly-syndactyly syndrome is a congenital skeletal developmental disorder caused by genetic mutations (most commonly involving ROR2 or related developmental genes). The structural abnormalities arise during embryogenesis and cannot be corrected by post-natal anti-inflammatory therapy. There is no biological pathway through which Sulfasalazine’s anti-inflammatory mechanisms could plausibly influence the molecular defects underlying this syndrome.
The high TxGNN score (99.94%) most likely results from topological proximity between orthopaedic disease nodes in the knowledge graph (KG), rather than from any true pharmacological relationship. This is a recognised limitation of graph-based prediction algorithms: high scores can reflect shared network neighbourhood rather than genuine drug-disease biology. This prediction is considered a probable false positive and does not warrant further clinical investigation at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Netherlands Market Information
Sulfasalazine currently holds no marketing authorizations registered with the CBG-MEB (College ter Beoordeling van Geneesmiddelen). No SmPC (Samenvatting van de Productkenmerken) or PIL (Bijsluiter) data is available from the Dutch regulatory database for this product.
Safety Considerations
Please refer to the SmPC (Summary of Product Characteristics) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Brachydactyly-syndactyly syndrome is a congenital, genetically-determined skeletal disorder with no plausible pharmacological entry point for an anti-inflammatory DMARD such as Sulfasalazine. The very high TxGNN prediction score (99.94%) is most likely driven by knowledge-graph topological similarity rather than any genuine drug-disease signal; no clinical trial, observational study, or mechanistic publication exists to support this hypothesis.
To proceed, the following is needed:
- A credible biological hypothesis demonstrating how Sulfasalazine’s known molecular pathways could influence the ROR2 (or equivalent) developmental signalling cascade underlying this syndrome — currently considered implausible
- Should any such mechanistic hypothesis emerge in future basic-science research, a targeted literature review and expert genetics consultation would be the mandatory first steps before any clinical consideration
- Separately, the NL regulatory data gap (0 CBG-MEB authorizations, missing SmPC) should be resolved to enable a proper safety baseline assessment of Sulfasalazine itself, independent of this repurposing question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.